The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots
Study Details
Study Description
Brief Summary
We propose a prospective cohort study to assess the effect of the progesterone only contraceptive pill (minipill) on coagulation parameters known to be associated with risk of thrombosis (blood clots) in women who are at increased risk for forming blood clots. We plan to recruit women with a history of venous thromboembolism (VTE, blood clot in a vein) and women with a history of blood tests which demonstrate an increased risk of thrombosis who desire contraception.
Women enrolled in this study will undergo phlebotomy (blood draw) at baseline (prior to starting the minipill), one and three months. Stored samples will be used to measure D-dimer, C-reactive protein (CRP), antithrombin (AT), factor VIII, free and total protein S, fibrinogen, von Willebrand factor (vWF) and normalized activated protein C sensitivity ratio (nAPCsr). Both groups will undergo a general physical and GYN exam prior to enrollment. This exam and the blood testing will be provided free of charge. Patients will not be prescribed the minipill after completion of the study and will be advised to consult with their primary care physician or hematologist if they wish to continue this medication.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| N/A |
Study Design
Outcome Measures
Primary Outcome Measures
- The primary outcome of this study will be change in coagulation parameters. The proposed sample size of 20 subjects was derived based on having sufficient power to detect a 40% change in the variable D-dimer, a lab measurement. [2 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women with a history of venous thromboembolism (VTE, blood clot in a vein) and women with a history of blood tests which demonstrate an increased risk of thrombosis who desire contraception.
-
Blood tests which demonstrate an increased risk of thrombosis include the following:
-
Hyperhomocysteinemia/MTHFR mutation
-
Prothrombin gene mutation
-
Factor V Leiden heterozygotes
-
Factor V Leiden homozygotes, antithrombin III mutation
-
Protein S deficiency and Protein C deficiency.
Exclusion Criteria:
-
Women on current anticoagulation therapy
-
Women with a history of oral contraceptive related thrombotic events
-
Active or history of cigarette smoking within the past 6 months
-
Pregnancy
-
Active lactation
-
Known hypersensitivity to progestin
-
Any history of malignancy
-
History within the last three months of surgery or planning surgery during the study period
-
Undiagnosed vaginal bleeding
-
Active liver disease and history within the last 5 years of alcoholism or drug abuse.
-
Additionally, women must be greater than 3 months postpartum and have had two months without contraceptive hormones (such as the birth control pill) and 6 months without Depo-Provera use prior to enrollment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Vermont | Burlington | Vermont | United States | 05405 |
Sponsors and Collaborators
- University of Vermont
Investigators
- Principal Investigator: Kristen P Wright, MD, University of Vermont
- Principal Investigator: Julia V Johnson, MD, University of Vermont
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 08-002